Skip to search formSkip to main contentSkip to account menu

Lisinopril

Known as: N2-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline, Dihydrate, (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, [N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline 
An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A case report of therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis. 
2005
2005
This editorial refers to ‘Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial… 
2003
2003
The present study was designed to evaluate the effect of combination therapy using the angiotensin-converting enzyme-inhibitor… 
1998
1998
A chemical interaction between lisinopril and lactose was demonstrated and quantified in dilute mixtures in the solid state. 
1995
1995
The comparative effects on echocardiographically determined left ventricular (LV) mass and pulsed Doppler derived indexes of LV… 
1994
1994
Summary The effects of single oral doses of lisinopril (5 and 20 mg) on systemic and regional hemodynamics were investigated… 
1992
1992
The interaction of angiotensin-converting enzyme (ACE) inhibitors and bradykinin was investigated in isolated bovine and human… 
1989
1989
: Established essential hypertension is characterised haemodynamically by a normal cardiac output and elevated total peripheral… 
1987
1987
The effect of the converting enzyme inhibitor lisinopril on renal and cardiac hemodynamics was studied in patients with moderate…